Key Drivers
- Strong gross margin
- Negative cash flow
- Heavy loss carryover
AIAI Summary
MYGN is shifting from a turnaround to a clinical-validation and rollout story, but despite ~70% gross margins the business still burns cash and needs faster adoption of Precise MRD/Prolaris-led growth to prove that recent momentum can translate into sustained earnings power.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong gross margin
- •Negative cash flow
- •Heavy loss carryover
MYGN has solid revenue, gross margin, and liquidity, but persistent operating losses, negative free cash flow, and a large accumulated deficit make it a high-risk turnaround story rather than a clear value opportunity.
Price Behavior
Key Price Behavior Insights:
- •Sharp uptrend
- •Consolidation hold
- •Near resistance
MYGN has trended sharply higher from $4.38 to $6.18, with consolidation above recent support but now nearing $6.30-$6.31 resistance, so upside looks strongest only on a breakout and hold above that level.
Sharp rally from $4.38 to $6.18 over the last month suggests stretched momentum risk
Sentiment & News
Key News Insights:
- •Test expansion
- •Clinical validation
- •Growth potential
Myriad Genetics' late-June to mid-July updates point to expanding test adoption and stronger clinical evidence, supporting growth prospects even as investor sentiment and analyst revisions remain cautious.
These headlines are modestly positive for MYGN by reinforcing product momentum and evidence-based adoption, though near-term upside may stay capped by mixed market and earnings sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings